Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pharmacist Follow-up, a Qualitative Study of Patient Experience

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2010 by Hospital Pharmacy of North Norway Trust.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
University of Tromso
Information provided by:
Hospital Pharmacy of North Norway Trust
ClinicalTrials.gov Identifier:
NCT01131715
First received: April 30, 2010
Last updated: May 26, 2010
Last verified: May 2010
  Purpose

A pharmacist follow-up procedure is under development. Patients with coronary heart disease (CHD) is being followed up by a pharmacist for one year with three meetings; at discharge from hospital, after three months and after one year. The evaluation is basically based on quantitative measures as achievement of therapeutic goals, number of drug related problems detected, hospitalisations etc. However, the patients' own experience with the follow-up procedure cannot be evaluated using these measures. Thus, a qualitative approach is needed. In this study, a total of four patients participating in the follow-up will be included and interviewed. A semistructured interview guide will be used. Interviews will be taped, transcribed and analyzed with the intention to explore how patients experience the follow-up from the pharmacist. A thoruough content analysis will be performed. Patients included must have met the pharmacist at least twice. The pharmacist in charge of the follow-up will recruit patients and hand out study information. Patients will reply to the principal investigator of the study and thus kept anonymous for the pharmacist in charge of the follow-up. No pressure will be put on the patients to join, but it will be emphasized that it will help evaluating the procedure.


Condition
Patient Satisfaction
Patient Preference

Study Type: Observational
Official Title: Pharmacist Follow-up of Patients With Coronary Heart Disease. A Qualitative Study of Patient Experience.

Resource links provided by NLM:


Further study details as provided by Hospital Pharmacy of North Norway Trust:

Primary Outcome Measures:
  • Qualitative evaluation of the impact of pharmacist follow-up via interviews with the participating patients [ Time Frame: 3 months or 1 year ] [ Designated as safety issue: No ]
    In the pharmacist follow-up procedure under development, patients have individual "consultations" with a pharmacist three times. Patients are recruited to this study at the second or third consultation. Interviews will be performed with patients included to explore how patients' experience this follow-up procedure. Outcome measures from patient interviews can be counted. In qualitative research, the content of the interviews are thoroughly analysed with focus on the meaning of the informant's/interviewee's sayings. Outcomes will be presented as overall themes touched by the informants.


Enrollment: 4
Study Start Date: March 2010
Estimated Study Completion Date: July 2010
Estimated Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Study group
Patients who are included in the pharmacist follow-up procedure

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients included in the study "Pharmacist follow-up of patients with CHD".

Criteria

Inclusion Criteria:

  • must have met the pharmacist at least twice
  • living within the area of Tromsoe city so that interviews are possible

Exclusion Criteria

  • none as patients are already enrolled in another study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01131715

Locations
Norway
University of Tromsoe
Tromso, Norway, 9037
Sponsors and Collaborators
Hospital Pharmacy of North Norway Trust
University of Tromso
Investigators
Principal Investigator: Lars Smaabrekke, PhD University of Tromso
Study Chair: Beate H Garcia, PhDstudent Hospital Pharmacy of North Norway Trust
  More Information

No publications provided by Hospital Pharmacy of North Norway Trust

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Lars Smaabrekke, University of Tromsø
ClinicalTrials.gov Identifier: NCT01131715     History of Changes
Other Study ID Numbers: SHAN-002
Study First Received: April 30, 2010
Last Updated: May 26, 2010
Health Authority: Norway: Ethics Committee

Keywords provided by Hospital Pharmacy of North Norway Trust:
Qualitetive interview
Coronary heart disease (CHD)
Patient experience
Patient perception

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Arterial Occlusive Diseases
Arteriosclerosis
Cardiovascular Diseases
Heart Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on November 27, 2014